{"id":"NCT01256684","sponsor":"EndoCeutics Inc.","briefTitle":"DHEA Against Vaginal Atrophy - 3-Month Efficacy Study","officialTitle":"DHEA Against Vaginal Atrophy (Placebo-controlled, Double-blind and Randomized Phase III Study of 3-month Intravaginal DHEA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2011-08","completion":"2011-11","firstPosted":"2010-12-08","resultsPosted":"2017-04-25","lastUpdate":"2017-06-26"},"enrollment":255,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Vaginal Atrophy"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"DHEA","otherNames":["Prasterone, Dehydroepiandrosterone"]},{"type":"DRUG","name":"DHEA","otherNames":["Prasterone, Dehydroepiandrosterone"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"0.25% DHEA","type":"EXPERIMENTAL"},{"label":"0.5% DHEA","type":"EXPERIMENTAL"}],"summary":"The purpose of this Phase III trial is to confirm the efficacy of intravaginal dehydroepiandrosterone (DHEA) in postmenopausal women with vaginal atrophy.","primaryOutcome":{"measure":"Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo","deltaMin":68.48,"sd":4.41},{"arm":"0.25% DHEA","deltaMin":65.72,"sd":4.56},{"arm":"0.50% DHEA","deltaMin":65.05,"sd":4.63}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":33,"countries":["United States","Canada"]},"refs":{"pmids":["25734980","25968836","26972555"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":80},"commonTop":["Application site discharge","Urinary tract infection"]}}